PLSMHealthcare · Medical DevicesPLSM Stock Forecast: Pulsenmore Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 1 Aug 2026 — in the lower half.
PLSM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Pulsenmore Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Volatility (1): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Pulsenmore Ltd. — and when they’d sell — is the membership.
PLSM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLSM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLSM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Pulsenmore Ltd. (PLSM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.5×
- Price / sales
- 0.6×
- Price / book
- —
- EV / EBITDA
- −0.5×
Cheaper than 83% of US stocks
Cheaper than 80% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- 578.3%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −38.8%
- Net margin
- −39.6%
Higher than 98% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
- Return on equity
- −17.6%
- Return on assets
- −6.2%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PLSM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLSM appears on the weeks it earns a place.
Frequently asked questions about PLSM stock
How does Ticker Nerd's model rank PLSM?
As at 1 Aug 2026, Pulsenmore Ltd. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
What is the PLSM stock forecast for 2030?
No analyst covering Pulsenmore Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSM are extrapolating price history, which says nothing about the business.
What does Pulsenmore Ltd. do?
Pulsenmore Ltd. is a healthcare technology company that develops and markets home-use ultrasound and digital health solutions focused primarily on prenatal care.
About Pulsenmore Ltd.
Pulsenmore Ltd. is a healthcare technology company that develops and markets home-use ultrasound and digital health solutions focused primarily on prenatal care. The company’s core offering is a self-scan ultrasound system that combines a handheld ultrasound cradle that docks with a patient’s smartphone, a dedicated mobile application, and secure cloud infrastructure for image transmission and storage. This setup enables pregnant women to perform guided scans at home, with images and video made available for physician-supervised review and remote clinical assessment. Pulsenmore Ltd. serves the broader telehealth, digital health, and femtech segments by supporting remote monitoring, reducing dependence on in-clinic visits, and integrating with clinician dashboards and workflows. Headquartered in Israel, the company positions its technology as an infrastructure component for healthcare providers and payers seeking to expand remote prenatal services and improve continuity of care within existing medical systems.
CEO Dr. Elazar Sonnenschein · 71 employees · Israel · https://www.pulsenmore.com